Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities: 2022-2025

Historic Total Liabilities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $62.9 million.

  • Day One Biopharmaceuticals' Total Liabilities rose 38.74% to $62.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 38.74%. This contributed to the annual value of $80.0 million for FY2024, which is 171.24% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Total Liabilities stood at $62.9 million, which was up 8.09% from $58.2 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Total Liabilities registered a high of $93.7 million during Q2 2024, and its lowest value of $8.2 million during Q1 2022.
  • Moreover, its 3-year median value for Total Liabilities was $45.3 million (2024), whereas its average is $47.9 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Total Liabilities spiked by 279.35% in 2024, and later slumped by 37.89% in 2025.
  • Day One Biopharmaceuticals' Total Liabilities (Quarterly) stood at $17.0 million in 2022, then surged by 73.34% to $29.5 million in 2023, then skyrocketed by 171.24% to $80.0 million in 2024, then skyrocketed by 38.74% to $62.9 million in 2025.
  • Its last three reported values are $62.9 million in Q3 2025, $58.2 million for Q2 2025, and $54.8 million during Q1 2025.